Side Effects of Drugs Annual - 1st Edition - ISBN: 9780444634078, 9780444633910

Side Effects of Drugs Annual, Volume 36

1st Edition

A worldwide yearly survey of new data in adverse drug reactions

Serial Volume Editors: Sidhartha Ray
eBook ISBN: 9780444633910
Hardcover ISBN: 9780444634078
Imprint: Elsevier
Published Date: 10th December 2014
Page Count: 836
Sales tax will be calculated at check-out Price includes VAT/GST
25% off
25% off
25% off
25% off
25% off
20% off
20% off
25% off
25% off
25% off
25% off
25% off
20% off
20% off
25% off
25% off
25% off
25% off
25% off
20% off
20% off
377.00
282.75
282.75
282.75
282.75
282.75
301.60
301.60
229.00
171.75
171.75
171.75
171.75
171.75
183.20
183.20
285.00
213.75
213.75
213.75
213.75
213.75
228.00
228.00
Unavailable
Price includes VAT/GST
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  • Side Effects of Drugs Annual
  • Preface
  • Special Reviews in SEDA-36
  • Table of Essays, Annuals 1–35
  • Mechanistic and Clinical Descriptions of Adverse Drug Reactions
    • EIDOS
    • DoTS
  • Definitive (Between-the-Eyes) Adverse Drug Reactions
  • How to Use This Book
    • The Scope of the Side Effects of Drugs Annuals
    • Allocation of Drugs to Chapters
  • Abbreviations
  • Classification of Immunological Reactions
    • Other Types of Reactions
  • Classification of Drug Teratogenicity
  • Grades of Adverse Drug Reactions
  • Chapter 1. Central Nervous System Stimulants and Drugs that Suppress Appetite
    • Amphetamine and Amphetamine Derivates [SEDA-15, 180; SEDA-32, 1; SEDA-33, 1; SEDA-34, 1]
    • Methylphenidate [SEDA-15, 2307; SEDA-32, 10; SEDA-33, 7; SEDA-34, 5]
    • Methylxanthines
    • Selective Norepinephrine Reuptake Inhibitors Atomoxetine [SEDA-33, 6; SEDA-34, 4]
    • Vigilance Promoting Drugs
    • Drugs that Suppress Appetite [SEDA-30, 7; SEDA-32, 16; SEDA-33, 13; SEDA-34, 8]
    • Parasympathomimetics [SEDA-32, 19; SEDA-33, 15; SEDA-34, 9]
  • Chapter 2. Antidepressant Drugs
    • General
    • Selective Serotonin Reuptake Inhibitors [SED-15, 3109; SEDA-31, 18; SEDA-32, 33; SEDA-33, 26; SEDA-34, 17; SEDA-35, 30]
    • Serotonin and Noradrenaline Reuptake Inhibitors
    • Tricyclic Antidepressants
    • Other Antidepressants
  • Chapter 3. Lithium
    • Lithium Toxicity
  • Chapter 4. Drugs of Abuse
    • Cannabinoids
    • Cocaine
    • Ecstasy (3,4-Methylenedioxymetamfetamine)
  • Chapter 5. Hypnosedatives and Anxiolytics
    • Benzodiazepines [SED-15, 429; SEDA-31, 57; SEDA-32, 75; SEDA-33, 71; SEDA-34, 45]
    • Hypnosedatives and Benzodiazepine-Like Drugs [SED-15, 3710; SEDA-33, 78; SEDA-34, 47]
  • Chapter 6. Antipsychotic Drugs
    • General [SED-15, 2438; SEDA-32, 83; SEDA-33, 89; SEDA-34, 51; SEDA-35, 85]
    • Individual Drugs
  • Chapter 7. Antiepileptic Drugs
    • Rx Pharmacogenomics and Antiepileptic Medications
    • General
    • Comparative Studies
    • Ethosuximide
  • Chapter 8. Opioid Analgesics and Narcotic Antagonists
    • Rx: Opioid Abuse Epidemic and the Role of Take-Home Naloxone
    • Alfentanil [SED-15, 72; SEDA-33, 209; SEDA-34, 152; SEDA-35, 173]
    • Codeine [SED-15, 880; SEDA-33, 209; SEDA-34, 152; SEDA-35, 174]
    • Dextrometrophan [SED-15, 1088; SEDA-33, 210; SEDA-34, 153; SEDA-35, 174]
    • Diamorphine [SED-15, 1096; SEDA-33, 210; SEDA-34, 153; SEDA-35, 175]
    • Dihydrocodeine [SED-15, 1125; SEDA-33, 211; SEDA-34, 154; SEDA-35, 175]
    • Fentanyl [SED-15, 1346; SEDA-33, 211; SEDA-34, 154; SEDA-35, 176]
    • Hydrocodone [SED-15, 1702; SEDA-34, 156; SEDA-35, 177]
    • Methadone [SED-15, 2270; SEDA-33, 214; SEDA-34, 157; SEDA-35, 177]
    • Morphine [SED-15, 2386; SEDA-33, 216; SEDA-34, 159; SEDA-35, 181]
    • Oxycodone [SED-15, 2651; SEDA-33, 219; SEDA-34, 161; SEDA-35, 182]
    • Papaverine [SED-15, 2678; SEDA-33, 221; SEDA-34, 162; SEDA-35, 183]
    • Pethidine (Meperidine) [SED-15, 2791; SEDA-33, 221; SEDA-34, 163; SEDA-35, 183]
    • Remifentanyl [SED-15, 3030; SEDA-33, 222; SEDA-34, 163; SEDA-35, 184]
    • Tramadol [SED-15, 3469; SEDA-33, 224; SEDA-34, 165; SEDA-35, 184]
    • Buprenorphine [SED-15, 571; SEDA-33, 225; SEDA-34, 166; SEDA-35, 185]
    • Methylnaltrexone [SED-15, 2307; SEDA-33, 227; SEDA-34, 168; SEDA-35, 186]
    • Naloxone [SED-15, 2421; SEDA-33, 227; SEDA-35, 186]
    • Naltrexone [SED-15, 2423; SEDA-33, 228; SEDA-34, 168; SEDA-35, 186]
  • Chapter 9. Anti-inflammatory and Antipyretic Analgesics and Drugs Used in Gout
    • Nonsteroidal Anti-inflammatory Drugs
    • Arylalkanoic Acid Derivatives [SED-15, 2555; SEDA-32, 229; SEDA-33, 245; SEDA-34, 185, SEDA-35, 200]
    • COX-2 Selective Inhibitors [SEDA-30, 130; SEDA-32, 232; SEDA-33, 246; SEDA-34, 186, SEDA-35, 201]
    • Celecoxib [SED-15, 685; SEDA-32, 233; SEDA-33, 246; SEDA-34, 186, SEDA-35, 201]
    • Etoricoxib
    • Rofecoxib [SED-15, 3076; SEDA-32, 233; SEDA-33, 247; SEDA-34, 187, SEDA-35, 201]
    • Oxicams [SEDA-15, 2555; SEDA-32, 233; SEDA-33, 247; SEDA-34, 187, SEDA-35, 201]
    • Propionic Acid Derivatives
    • Salicylates [SED-15, 15; SEDA-33, 248; SEDA-34, 188, SEDA-35, 202]
    • Nefopam [SED-15, 2433; SEDA-34, 188, SEDA-35, 207]
    • Nimesulide
    • Febuxostat [SEDA-32, 235; SEDA-33, 250, SEDA-35, 209]
    • Rasburicase [SEDA-32, 236; SEDA-33, 250, SEDA-35, 209]
  • Chapter 10. General Anaesthetics and Therapeutic Gases
    • Anaesthetic Vapours [SEDA-32, 243; SEDA-33, 257; SEDA-34, 195; SEDA-35, 217]
    • Isoflurane [SED-15, 1921; SEDA-33, 258; SEDA-34, 196; SEDA-35, 218]
    • Sevoflurane [SED-15, 3123; SEDA-33,258; SEDA-34, 196; SEDA-35, 219]
    • Other Vapours
    • Intravenous Agents: Non-barbiturate Anaesthetics
  • Chapter 11. Local Anesthetics
    • General Information
    • Effects Related to Mode of Use
    • Caudal, Epidural and Spinal Anesthesia
    • Individual Compounds
  • Chapter 12. Neuromuscular Blocking Agents and Skeletal Muscle Relaxants
    • Depolarising Neuromuscular Blocking Agents
    • Skeletal Muscle Relaxants
    • Organs and Systems
    • Susceptibility Factors
    • Botulinum Toxins
    • Organs and Systems
    • Cyclobenzaprine
    • Organ Systems
    • Tizanidine
    • Drug Interactions
  • Chapter 13. Drugs that Affect Autonomic Functions or the Extrapyramidal System
    • Drugs That Act on Alpha- and Beta-Adrenoceptors [SEDA-31,259; SEDA-32, 281, SEDA-33, 313, SEDA-34,233; SEDA-35, 225]
    • Drugs That Predominatly Act on Alpha1-Adrenoceptors [SEDA-33, 318, SEDA-34,236, SEDA-35, 257]
    • Drugs That Act on Beta1-Adrenoceptors [SEDA-33, 265, SEDA-34,285, SEDA-35,257]
    • Drugs That Act on Beta2-Adrenoceptors
    • Drugs That Act on Dopamine Receptors [SEDA-33, 266, SEDA-34,283, SEDA-35, 258]
    • Drugs That Affect the Cholinergic System [SEDA-33, 324, SEDA-34,290-1,318, SEDA-35, 266]
  • Chapter 14. Dermatological Drugs, Topical Agents, and Cosmetics
    • Acitretin
    • Arsenic Trioxide
    • Benzoyl Peroxide
    • Budesonide
    • Calcipotriol
    • Chemoradiation Therapy
    • Collagen Vascular Diseases
    • Cosmetics and Creams
    • Cytokines
    • Dermatitis
    • Detergents and Caustic Substances
    • Difluprednate
    • Dressing
    • Finasteride
    • Fluocinolone
    • Hair Dye
    • Hyaluronic Acid
    • Hydroxycarbamide
    • Hydroxyurea
    • Isotretinoin
    • Laser Therapies
    • Mouthwashes
    • Photodynamic Therapy
    • Prednisolone
    • Prednisone and Other Corticosteroids
    • PUVA
    • Retinoic Acid
    • Silicon Oil
    • Steroids
    • Sunscreens
    • Tannic Acid
    • Trichloracetic Acid
    • Vitamin D
  • Chapter 15. Antihistamines (H1 Receptor Antagonists)
    • General
    • Other Antihistamines
  • Chapter 16. Drugs that Act on the Respiratory Tract
    • Inhaled Glucocorticoids [SEDA-32, 311; SEDA-33, 353; SEDA-34, 277; SEDA-35, 309]
    • Nasal Glucocorticoids [SEDA-34, 279; SEDA-35, 314]
    • Beta2-Adrenoceptor Agonists [SEDA-32, 314; SEDA-33, 357; SEDA-34, 280; SEDA-35, 315]
    • Anticholinergic Drugs [SEDA-32, 318; SEDA-33, 363; SEDA-34, 282; SEDA-35, 318]
    • Leukotriene Modifiers [SEDA-32, 319; SEDA-33, 366; SEDA-34, 283; SEDA-35, 320]
    • Phosphodiesterase Inhibitors [SEDA-32, 321; SEDA-33, 367; SEDA-34, 284; SEDA-35, 321]
    • Mucolytic Drugs [SEDA-32, 325; SEDA-33, 369; SEDA-35, 321]
    • Antitussive Drugs [SEDA-35, 322]
  • Chapter 17. Positive Inotropic Drugs and Drugs Used in Dysrhythmias
    • Cardiac Glycosides [SEDA-15, 648; SEDA-32, 333; SEDA-33, 377; SEDA-34]
    • Other Positive Inotropic Drugs [SEDA-15, 2822; SEDA-32, 336; SEDA-33, 378; SEDA-34, 290]
    • Antidysrhythmic Drugs
    • Ajmaline [SEDA-15, 45; SEDA-34, 292]
    • Amiodarone [SEDA-15, 148; SEDA-32, 339; SEDA-33, 380; SEDA-34,292]
    • Bepridil [SEDA-15, 445; SEDA-33, 384; SEDA-34, 295]
    • Cibenzoline [SEDA-15, 740; SEDA-32, 347; SEDA-33, 385; SEDA-34, 296]
    • Dronedarone [SEDA-33, 386; SEDA-34, 296]
    • Flecainide [SEDA-15, 1370; SEDA-32, 348; SEDA-33, 387; SEDA-34, 297]
    • Propafenone [SEDA-15, 2939; SEDA-33, 389; SEDA-34, 298]
    • Ranolazine
  • Chapter 18. β-Adrenoceptor Antagonists and Antianginal Drugs
    • β-Adrenoreceptor Antagonists [SED-15, 452; SEDA-32, 363; SEDA-33, 397; SEDA-34, 303; SEDA-35, 351]
    • Labetalol [SED-15, 1985; SEDA-32, 364; SEDA-33, 399; SEDA-34, 304; SEDA-35, 351]
    • Metoprolol [SEDA-35, 352]
    • Propranolol [SEDA-35, 352]
    • Potassium Channel Activators
    • Nitrates, Organic [SED-15, 2529; SEDA-32, 366; SEDA-33, 400; SEDA-34, 305; SEDA-35, 354]
    • Calcium Channel Blockers [SED-15, 598; SEDA-32, 366; SEDA-33, 401; SEDA-34, 306; SEDA-35, 354]
    • Nicardipine [SED-15, 2502; SEDA-32, 367; SEDA-33, 402; SEDA-34, 308; SEDA-35, 355]
    • Nifedipine [SED-15, 2516; SEDA-33, 402; SEDA-34, 308; SEDA-35, 355]
    • Verapamil [SED-15, 3618; SEDA-32, 367; SEDA-33, 403; SEDA-34, 308; SEDA-35, 356 ]
    • Carvedilol
    • Cardiovascular
  • Chapter 19. Drugs Acting on the Cerebral and Peripheral Circulations
    • Drugs Used in the Treatment of Arterial Disorders of the Brain and LIMBS
    • Drugs Used in the Treatment of Migraine
    • Other Peripheral Vasodilators
  • Chapter 20. Antihypertensive Drugs
    • General
    • Angiotensin-Converting Enzyme Inhibitors [SED-15, 226; SEDA-33, 416; SEDA-34, 321; SEDA-35,364]
    • Angiotensin Receptor Blockers/Angiotension II /Receptor Antagonists [SEDA-15, 2071; SEDA-34 324, SEDA-35]
    • Dual Angiotensin II Receptor Antagonists/Neprilysin Antagonists
    • Direct Renin Inhibitors [SEDA-33, 420; SEDA-34, 328; SEDA-35, 373]
    • Direct Vasodilators
    • Endothelin Receptor Antagonists [SED-15, 1215; SEDA-33, 421; SEDA-34, 328; SEDA-35, 374]
    • Drugs that Act on the Sympathetic Nervous System [SEDA-33, 424; SEDA-34, 329; SEDA-35, 376]
    • Postsynaptic Alpha-Adrenoceptor Antagonists [SEDA-33, 425; SEDA-34, 330; SEDA-35, 377]
  • Chapter 21. Diuretics
    • Carbonic Anhydrase Inhibitors [SEDA-15, 643; SEDA-32, 403; SEDA-33, 437; SEDA-34, 339; SEDA-34, 387]
    • Loop Diuretics [SEDA-15, 567, 1454; SEDA-32, 408; SEDA-33, 440; SEDA-34, 342; SEDA-35, 390]
    • Thiazide and Thiazide-Like Diuretics [SEDA-15, 3375; SEDA-32, 405; SEDA-33, 438; SEDA-34, 340; SEDA-35, 388]
    • Aldosterone Receptor Antagonists
    • Osmotic Diuretics
  • Chapter 22. Metals
    • Aluminium [SED-15, 97; SEDA-32, 413; SEDA-33, 447; SEDA-34, 349]
    • Antimony and Antimonials [SED-15, 316; SEDA-32, 414; SEDA-33, 448; SEDA-34, 350]
    • Arsenic [SED-15, 339; SEDA-32, 414; SEDA-33, 448; SEDA-34, 351]
    • Beryllium [SEDA-34, 353]
    • Calcium Salts [SED-15, 610; SEDA-33, 449; SEDA-34, 354]
    • Chromium [SED-15, 737; SEDA-32, 414; SEDA-33, 450; SEDA-34, 354]
    • Cobalt [SED-15, 847; SEDA-32, 415; SEDA-33, 450; SEDA-34, 354]
    • Copper [SED-15, 901; SEDA-32, 415; SEDA-33, 450; SEDA-34, 355]
    • Gold and Gold Salts [SED-15, 1520; SEDA-32, 416; SEDA-33, 451; SEDA-34, 355]
    • Iron Salts [SED-15, 1911; SEDA-32, 417; SEDA-33, 451; SEDA-34, 355]
    • Lanthanum Carbonate [SEDa-32, 417; SEDA-33, 451; SEDA-34, 356]
    • Lead [SED-15, 2013; SEDA-28, 247]
    • Magnesium Salts [SED-15, 2196; SEDA-32, 417; SEDA-33, 452; SEDA-34, 356]
    • Manganese [SED-15, 2200; SEDA-32, 418; SEDA-33, 452; SEDA-34, 357]
    • Mercury and Mercurial Salts [SED-15, 2259; SEDA-32, 419; SEDA-33, 453; SEDA-34, 358]
    • Nickel [SED-15, 2502; SEDA-32, 419; SEDA-33, 453; SEDA-34, 358]
    • Potassium Salts [SED-15, 2905; SEDA-31, 392]
    • Silver Salts and Derivatives [SED-15, 3140; SEDA-32, 420; SEDA-33, 454; SEDA-34, 359]
    • Strontium Salts [SEDA-32, 420; SEDA-33, 455; SEDA-34, 359]
    • Titanium [SED-15, 3434; SEDA-32, 420; SEDA-33, 456; SEDA-34, 360]
    • Zinc [SED-15, 3717; SEDA-32, 420; SEDA-33, 458; SEDA-34, 360]
  • Chapter 23. Metal Antagonists
    • Metal Antagonists
    • Organs and Systems
    • Susceptibility Factors
    • Drug Administration
    • Paediatric
    • Paediatric
    • Sensory Systems
    • Deferiprone and Deferoxamine
    • Deferasirox, Deferiprone and Deferoxamine
    • Hydroxyurea
    • Organ Toxicitiy
  • Chapter 24. Antiseptic Drugs and Disinfectants
    • Aldehydes [SED-15, 1439, 1513; SEDA-31, 409; SEDA-32, 437; SEDA-33, 479; SEDA-34, 377]
    • Guanidines
    • Benzalkonium Compounds [SED-15, 421; SEDA-32, 440; SEDA-33, 481; SEDA-34, 379]
    • Ethylene Oxide [SED-15, 1296; SEDA-29, 242; SEDA-34, 379]
    • Triclosan [SEDA-34, 379]
    • Halogens
    • Phenolic Compounds [SED-15, 2800; SEDA-32, 441; SEDA-33, 485; SEDA-34, 381]
  • Chapter 25. Penicillins, Cephalosporins, Other Beta-Lactam Antibiotics and Tetracyclines
    • Tetracycylines and Glycylcyclines
    • Organs and Systems
    • Interactions
    • Management of Adverse Drug Reactions
    • Organ Systems
    • Penicillins
    • Second-Generation Effects
    • Cephalosporins
    • Organs and Systems
    • Organ Systems
    • Drug Administration
    • Organ Systems
    • CNS
    • Interactions
    • Carbapenems
    • Second-Generation Effects
    • Interactions
    • Interactions
  • Chapter 26. Miscellaneous Antibacterial Drugs
    • Aminoglycosides [SED-15, 118; SEDA-32, 461; SEDA-33, 509; SEDA-34, 399, SEDA 35, 463]
    • Fluoroquinolones [SEDA-15, 1396; SEDA-32, 464; SEDA- 33, 514; SEDA-34, 401; SEDA-36, 464]
    • Glycopeptides [SEDA-32, 469; SEDA-33, 519; SEDA-34, 405; SEDA-35, 466]
    • Ketolides [SED-15, 1976; SEDA-32, 471; SEDA-33, 521; SEDA- 34, 407; SEDA-35, 469]
    • Lincosamides [SED-15, 2063; SEDA-32, 472; SEDA-33, 522; SEDA-34, 407; SEDA-35, 469]
    • Macrolides [SED-15, 2183; SEDA-32, 472; SEDA-33, 522; SEDA-34, 408; SEDA-35, 469]
    • Oxazolidinones [SED-15, 2645; SEDA-32, 474; SEDA-33, 525; SEDA-34, 409; SEDA-35, 471]
    • Polymyxins [SED-15, 2891; SEDA-32, 476; SEDA-33, 527; SEDA-34, 412; SEDA-35, 473]
    • Streptogramins [SED-15, 3182; SEDA-32, 528; SEDA-34, 413; SEDA-35, 473]
    • Trimethoprim, and Co-trimoxazole [SED-15, 3216, 3510; SEDA-32, 477; SEDA-33, 528; SEDA-34, 414; SEDA-35, 474]
    • Other Antimicrobial Drugs
  • Chapter 27. Antifungal Drugs
    • Allylamines [SED-33, 541; SEDA-34, 427; SEDA-35, 483]
    • Amphotericin [SEDA-15, 192; SEDA-33, 542; SEDA-34, 427; SEDA-35, 483]
    • Antifungal Azoles [SEDA-15, 301; SEDA-33, 545; SEDA-34, 428; SEDA-35, 484]
    • Echinocandins [SEDA-15, 1197; SEDA-33, 556; SEDA-34, 434; SEDA-35, 489]
  • Chapter 28. Antiprotozoal Drugs
    • Antimalarials
    • 4-Aminoquinolones (Chloroquine and Congeners) [SEDA-32, 521; SEDA-33, 567; SEDA-34, 441; SEDA-35, 495]
    • Quinine and Congeners [SED-15, 3002; SEDA-32, 524; SEDA-33, 570; SEDA-35, 499]
    • Endoperoxides [SED-15, 342; SEDA-32, 525; SEDA-33, 571; SEDA-34, 442, SEDA-35, 499]
    • Drugs Used in the Treatment of Other Protozoal Infections
  • Chapter 29. Antiviral Drugs
    • Drugs Active against Cytomegalovirus
    • Drugs Active against Hepatitis Viruses
    • Drugs Active against Human Immunodeficiency Virus: Combinations
    • Drugs Active against Human Immunodeficiency Virus: Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) [SED-15, 2586; SEDA-32, 534; SEDA-33, 585; SEDA-34, 456; SEDA-35, 516]
    • Drugs Active against Human Immunodeficiency Virus: Nucleotide Analogue Reverse Transcriptase Inhibitors
    • Drugs Active against Human Immunodeficiency Virus: Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) [SED-15, 2553;, SEDA-31, 486; SEDA-32, 537; SEDA-33, 590; SED-34, 459; SEDA-35, 519]
    • Drugs Active against Human Immunodeficiency Virus: Protease Inhibitors [SED-15, 2586; SEDA-32, 541; SEDA-33, 593; SEDA-34, 461, SEDA-35, 522]
    • Drugs Active against Human Immunodeficiency Virus: Inhibitors of HIV Fusion [SEDA-33; 598; SEDA-34, 464; SEDA-35, 525]
    • Drugs Active against Human Immunodeficiency Virus: Integrase Inhibitors [SEDA-33, 599, SEDA-34, 465, SEDA-35, 525]
    • Raltegravir
    • Drugs Active against Human Immunodeficiency Virus: Chemokine Receptor CCR5 Antagonists [SEDA-33, 600; SEDA 34, 465; SEDA-35, 528]
    • Drugs Active against Influenza Viruses: Ion Channel Inhibitors [SED-15, 105, 3051; SEDA-32, 544; SEDA-33, 269, 602; SEDA-34, 467; SEDA-35, 529]
    • Drugs Active against Influenza Viruses: Neuraminidase Inhibitors [SED-15, 2436; SEDA-32, 544; SEDA-33, 601; SEDA-34, 466; SEDA-35, 528]
    • Other Drugs
  • Chapter 30. Drugs Used in Tuberculosis and Leprosy
    • Tolerance of high dose Rifampicin
    • Isoniazid
    • Rifamycins
    • Ethambutol
    • Pyrazinamide
    • Fluoroquinolones
    • Linezolid
    • Cycloserine (CS)
    • Clofazimine
    • Bedaquiline (BDQ)
    • Delaminid
    • Dapsone
  • Chapter 31. Antihelminthic Drugs
    • Special Review
    • Albendazole
    • Diethylcarbamazine
    • Ivermectin
    • Levamisole
    • Mebendazole
    • Praziquantel
    • Tribendimidine
  • Chapter 32. Vaccines
    • General
    • Viral Vaccines
    • Bacterial Vaccines
  • Chapter 33. Blood, Blood Components, Plasma and Plasma Products
    • Albumin and Derivatives [SED-15, 54; SEDA-33, 670; SEDA-34, 509; SEDA-35, 583]
    • Blood Transfusion [SED-15, 529; SEDA-33, 671; SEDA-34, 509; SEDA-35, 583]
    • Blood Substitutes [SEDA-33, 672; SEDA-34, 511; SEDA-35, 586]
    • Plasma and Plasma Products [SED-15, 2847; SEDA-33, 674; SEDA-34, 512; SEDA-35, 586]
    • Plasma Substitutes [SEDA-33, 675; SEDA-34, 513; SEDA-35, 587]
    • Globulins
    • Coagulation Proteins [SED-15, 845; SEDA-32, 596; SEDA-33, 679; SEDA-34, 518]
    • Erythropoietin and Derivatives [SED-15, 1243; SEDA-33, 681; SEDA-34, 520; SEDA-35, 594]
    • Thrombopoietin and Receptor Agonists [SED-15, 3409]
    • Stem Cells [SEDA-33, 682; SEDA-34, 522; SEDA-35, 597]
  • Chapter 34. Vitamins, Amino Acids and Drugs and Formulations Used in Nutrition
    • Vitamin A (Carotenoids) [SED-15, 3642; SEDA-32, 607; SEDA-33, 691; SEDA-34, 531; SEDA-35, 607]
    • Vitamins of the B Group [SED-15, 2700; SEDA-32, 608; SEDA-33, 693; SEDA-34, 531; SEDA-35, 607]
    • Vitamin C (Ascorbic Acid) [SED-15, 351; SEDA-32, 611; SEDA-33, 694; SEDA-34, 531; SEDA-35, 609]
    • Vitamin D Analogues [SED-15, 3669; SEDA-32, 612; SEDA-33, 695; SEDA-34, 532; SEDA-35, 609]
    • Vitamin E (Tocopherol) [SED-15, 3677; SEDA-32, 612; SEDA-33, 696; SEDA-34, 533; SEDA-35, 610]
    • Vitamin K Analogues [SED-15, 3681; SEDA-34, 533; SEDA-35, 610]
    • Amino Acids
    • Parenteral Nutrition [SED-15, 2700; SEDA-32, 613; SEDA-33, 697; SEDA-34, 533; SEDA-35, 611]
    • Enteral Nutritionnteral [SED-15, 1221; SEDA-33, 700; SEDA-34, 536; SEDA-35, 611]
  • Chapter 35. Drugs that Affect Blood Coagulation, Fibrinolysis and Haemostasis
    • Coumarin Anticoagulants [SED-15, 983; SEDA-33, 707; SEDA-34, 541; SEDA-35, 617]
    • Heparins [SED-15, 1590; SEDA-33, 713; SEDA-34, 543; SEDA-35, 618]
    • Direct Thrombin Inhibitors [SED-15, 1142; SEDA-33, 717; SEDA-34, 544; SEDA-35, 619]
    • Direct Factor Xa Inhibitors [SEDA-33, 635; SEDA-34, 546; SEDA-35, 620]
    • Thrombolytic Drugs [SED-15, 3402; SEDA-35, 621]
    • Drugs that alter platelet Function [SEDA-33, 637; SEDA-34, 547; SEDA-35, 621]
    • Glycoprotein IIb–IIIa Inhibitors [SED-15, 4; SEDA-33, 720; SEDA-34, 548; SEDA-35, 622]
    • Thienopyridines [SED-15, 821; SEDA-33, 720; SEDA-34, 548; SEDA-35, 622]
    • Haemostatic Agents [SEDA-34, 549; SEDA-35, 624]
  • Chapter 36. Gastrointestinal Drugs
    • Antacids
    • Antiemetics and Drugs that Affect Gastrointestinal Motility
    • Dopamine Receptor Antagonists
    • 5HT3 Receptor Antagonists
    • Neurokinin NK1 Receptor Antagonists
    • Anti-Ulcer Agents
    • Laxatives and Oral Bowel Preparations
  • Chapter 37. Drugs that Act on the Immune System
    • Cytokines
    • Fusion Proteins
    • Monoclonal Antibodies [SED-15, 2380; SEDA-30, 442; SEDA-31, 602; SEDA-32, 686; SEDA-33, 783; SEDA-34, 586; SEDA-35, 672]
  • Chapter 38. Drugs that Act on the Immune System
    • Ciclosporin [SED-15, 743; SEDA-32, 705; SEDA-33, 815; SEDA-34, 609; SEDA-35, 699]
    • Cyclophosphamide [SED-15, 1025; SEDA-34, 612; SEDA-35, 700]
    • Everolimus (SDZ-RAD) [SED-15, 1306; SEDA-32, 708; SEDA-33, 817; SEDA-34, 614; SEDA-35, 701]
    • Fingolimod [SEDA-34, 616; SEDA-35, 703]
    • Glatiramer [SEDA-34, 617; SEDA-35, 703]
    • Leflunomide [SED-15, 2015; SEDA-32, 709; SEDA-33, 818; SEDA-34, 618; SEDA-35, 703]
    • Mycophenolate Mofetil [SED-15, 2402; SEDA-32, 710; SEDA-33, 819; SEDA-34, 622; SEDA-35, 704]
    • Sirolimus (Rapamycin) [SED-15, 3148; SEDA-32, 712; SEDA-33, 820; SEDA-34, 626; SEDA-35, 705]
    • Tacrolimus [SED-15, 3279; SEDA-32, 714; SEDA-33, 821; SEDA-34, 629; SEDA-35, 705]
    • Temsirolimus [SEDA-32, 716; SEDA-33, 824; SEDA-34, 632; SEDA-35, 707]
    • Thiopurines [SED-15, 377; SEDA-32, 717; SEDA-33, 824; SEDA-34, 633; SEDA-35, 709]
    • Immunoenhancing Drugs
  • Chapter 39. Corticotrophins, Corticosteroids and Prostaglandins
    • Corticotrophins [SED-15, 906; SEDA-33, 841; SEDA-34, 653; SEDA-35, 719]
    • Systemic Glucocorticoids [SED-15, 906; SEDA-33, 841; SEDA-34, 653; SEDA-35, 719]
    • Prostaglandins and Analogues [SED-15, 2955; SEDA-33, 846; SEDA-34, 660; SEDA-35, 725]
  • Chapter 40. Sex Hormones and Related Compounds, Including Hormonal Contraceptives
    • Oestrogens [SED-15, 1253; SEDA-32, 736; SEDA-33, 852; SEDA-34, 663; SEDA-35, 731 ]
    • Hormonal Contraceptives [SED-15, 1642; SEDA-32, 741; SEDA-33, 858; SEDA-34, 667; SEDA-35, 733]
    • Anti-oestrogens and Selective Oestrogen Receptor Modulators [SEDA-31, 664; SEDA-32, 743; SEDA-33, 859; SEDA-34, 669; SEDA-35, 735]
    • Progestogens [SED-15, 2930; SEDA-32, 747; SEDA-33, 865; SEDA-34, 671; SEDA-35, 736]
    • Progesterone Antagonists [SEDA-32, 749; SEDA-33, 866; SEDA-34, 671; SEDA-35, 738]
    • Anabolic Steroids, Androgens and Related Compounds [SED-15, 216; SEDA-32, 751; SEDA-33, 868; SEDA-34, 672; SEDA-35, 738]
    • Antiandrogens [SEDA-32, 755; SEDA-33, 872; SEDA-34, 674; SEDA-35, 740]
  • Chapter 41. Thyroid Hormones, Iodine and Iodides and Antithyroid Drugs
    • Thyroid Hormones [SEDA-31, 694; SEDA-32, 764; SEDA-33, 882; SEDA-34, 679; SEDA-35, 747]
    • Iodine and Iodides [SEDA 31, 684; SEDA 32, 764; SEDA 33, 883; SEDA 34, 680]
    • Antithyroid Drugs [SEDA-32,765; SEDA-33, 884; SEDA-34, 681; SEDA-35, 754]
  • Chapter 42. Insulin, Other Hypoglycaemic Drugs, and Glucagon
    • Glucagon [SEDA-15, 1510; SEDA-31, 689; SEDA-32, 769; SEDA-33, 889]
    • Insulin [SED-15, 1761; SEDA-31, 689; SEDA-32, 769; SEDA-33, 889; SEDA-34, 685]
    • Alpha-Glucosidase Inhibitors [SEDA-15, 85; SEDA- 30, 496; SEDA-31, 691; SEDA-32, 772; SEDA-33, 893]
    • Biguanides [SEDA-15, 506; SEDA-31, 692; SEDA-32, 773; SEDA-33, 893; SEDA-34, 687]
    • Dipeptidyl Peptidase 4 (DDP-4) Inhibitors [SEDA-31, 693; SEDA-32, 774; SEDA-33, 894; SEDA-34, 688]
    • Incretin Mimetics [SEDA-31, 695; SEDA-32, 775; SEDA-33, 896; SEDA-34, 690]
    • Meglitinides [SED-15, 2238; SEDA-31, 695; SEDA-32, 776; SEDA-33, 897; SEDA-34, 694]
    • Sodium–Glucose Transporter Type 2 (SGLT2) Inhibitors [SEDA-33, 898; SEDA-34, 695]
    • Sulphonylureas [SED-15, 3230; SEDA-31, 695; SEDA-32, 777; SEDA-33, 898; SEDA-34, 695]
    • Thiazolidinediones (Glitazones) [SED-15, 3380; SEDA-31, 697; SEDA-32, 779; SEDA-33, 899; SEDA-34, 696]
    • Rosiglitazone
    • Peroxisome Proliferator Activated Dual Receptor Agonists [SEDA-32, 782; SEDA-33, 902; SEDA-34, 698]
  • Chapter 43. Miscellaneous Hormones
    • Calcitonin [SED-15, 595; SEDA-33, 909; SEDA-34, 703; SEDA-35, 789]
    • Gonadotropins (Gonadorelin, GnRH and Analogues) [SED-15, 1536; SEDA-33, 909; SEDA-34, 703; SEDA-35, 789]
    • Gonadotrophin-Releasing Hormone Antagonists [SED-15, 1535; SEDA-34, 704; SEDA-35, 790]
    • Somatropin (Human Growth Hormone, hGH) [SED-15, 3163; SEDA-33, 910; SEDA-34, 704; SEDA-35, 791]
    • Growth Hormone Receptor Antagonists [SEDA-33, 911; SEDA-34, 708; SEDA-35, 792]
    • Melatonin and Analogues [SED-15, 2245; SEDA-33, 912; SEDA-34, 709; SEDA-35, 792]
    • Oxytocin and Analogues [SED-15, 2657; SEDA-33, 912; SEDA-34, 709; SEDA-35, 793]
    • Parathyroid Hormone [SED-15, 2689; SEDA-33, 913; SEDA-34, 711; SEDA-35, 794]
    • Somatostatin (Growth Hormone Release-Inhibiting Hormone) and Analogues [SED-15, 3160; SEDA-33, 913; SEDA-34, 711; SEDA-35, 794]
    • Vasopressin Receptor Antagonists [SEDA-34, 713; SEDA-35, 797]
    • Vasopressin and Analogues [SED-15, 3609; SEDA-33, 915; SEDA-34, 714; SEDA-35, 798]
  • Chapter 44. Drugs that Affect Lipid Metabolism
    • Combinations of Lipid-Modifying Drugs
    • Bile Acid Sequestrants [SED-15, 1902]
    • Cholesteryl Ester Transfer Protein Inhibitors [SEDA-32, 817; SEDA-33, 929; SEDA-34, 723; SEDA-35, 810]
    • Fibrates [SED-15, 1358; SEDA-32, 804; SEDA-33, 922; SEDA-34,724; SEDA-35, 812]
    • HMG-CoA Reductase Inhibitors [SED-15, 1632; SEDA-32, 807; SEDA-33, 924; SEDA-34, 725; SEDA-35, 812]
    • Nicotinic Acid Derivatives [SED-15, 2512; SEDA-32, 815; SEDA-33, 928; SEDA-34, 728; SEDA-35, 815]
  • Chapter 45. Anthracyclines
    • General Information
    • Organs and Systems
    • Long-Term Effects
    • Second-Generation Effects
    • Susceptibility Factors
    • Drug Administration
  • Chapter 46. Radiological Contrast Agents and Radiopharmaceuticals
    • Water-soluble Intravascular Iodinated Contrast Agents [SED-15, 1848; SEDA-33, 963; SEDA-34, 749; SEDA-35, 863]
    • MRI Contrast Media
    • Ultrasound Contrast Agents [SED-15, 3543; SEDA-32, 855; SEDA-33, 971; SEDA-34, 758; SEDA-35, 869]
    • Radiopharmaceuticals [SED-15, 3017; SEDA-33, 973; SEDA-34, 758; SEDA-35, 869]
  • Chapter 47. Drugs Used in Ocular Treatment
    • Drugs Used in the Management of Macular Degeneration [SEDA-31, 739; SEDA-32, 865; SEDA-33, 977]
    • Bevacizumab (See Also Chapter 37) [SEDA-32, 865; SEDA-33, 977]
    • Ranibizumab [SEDA-31, 739; SEDA-32, 867; SEDA-33, 978]
    • Antibacterial Drugs
    • Nonsteroidal Anti-Inflammatory Drugs
    • Iop-Lowering Medications
    • Glucocorticosteroids [SED-15, 906; SEDA-31, 741; SEDA-32, 871; SEDA-33, 983]
  • Chapter 48. Treatments Used in Complementary and Alternative Medicine
    • Asian Herbal Medicines
    • Nutritional Supplements
    • Specific Plants
  • Chapter 49. Miscellaneous Drugs, Materials, Medical Devices and Techniques
    • Adjuvants
    • Almitrine
    • Aluminium
    • Bisphosphonates
    • Calcium
    • Catheter
    • Choline
    • Citrate
    • Codeine
    • Collagen
    • Dipyridamole
    • Disulphiram
    • Drug Interactions
    • Etanercept
    • Fibrin
    • Fluoride
    • Gelatin
    • Hydroxyethyl Starch
    • Injection
    • Indigocarmine
    • Indocyanine
    • Iron
    • Latex Gloves
    • Magnesium
    • Melatonin
    • Methylene Blue
    • Menthol
    • Polyethylene Glycol
    • Poly-(L)-Lactic Acid
    • Potassium
    • Salt Supplement
    • Selenium Sulphide
    • Sevelamer
    • Silicone Oil
    • Strodium Ranelate
    • Talc
  • Reviewer List
  • Index of Drugs
  • Index of Drug-Drug Interactions
  • Index of Adverse Effects and Adverse Reactions

Description

The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.

Key Features

  • Provides a critical yearly survey of new data and trends on the side effects of drugs
  • Authored and reviewed by pioneers throughout the world in the clinical and practice sciences
  • An essential clinical on side effects of drugs for practitioners and healthcare professionals

Readership

Pharmacologists, clinicians, pharmaceutical companies, clinical toxicologists, clinical pharmacologists and medical libraries.


Details

No. of pages:
836
Language:
English
Copyright:
© Elsevier 2014
Published:
Imprint:
Elsevier
eBook ISBN:
9780444633910
Hardcover ISBN:
9780444634078

Ratings and Reviews


About the Serial Volume Editors

Sidhartha Ray Serial Volume Editor

Dr. Sidhartha D. Ray serves as a Professor of Pharmaceutical Sciences and was the Founding chair of that dept. at Manchester University College of Pharmacy in Fort Wayne, Indiana, USA. Prior to joining Manchester University, Dr. Ray served as Professor of Pharmaceutical Sciences for nearly 2 decades at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, New York. He is a teacher and a scholar, and teaches with passion such courses as mechanisms of drug action, molecular & cellular toxicology, toxic & side effects of drugs and chemicals, pathophysiology, medical microbiology and immunology. During his 31 years of academic experience in pharmacy teaching, research and service, Dr. Ray consistently maintained a rigorous research program focusing on drug & chemical induced organ toxicology, adverse drug reaction mechanisms, side effects of a number of therapeutically relevant drugs and environmentally significant stressors. Over the last two decades, Dr. Ray’s seminal discoveries have provided clear understandings on the dynamic role of apoptosis and necrosis in drug-induced organ toxicity and have influenced the development of safety measures for a stunning variety of xenobiotics, phytochemicals and nutraceuticals. He is internationally recognized as a leader in the scientific community and was one of the front runners in exploring mechanisms of drug and chemical-induced programmed and un-programmed cell death in in-vivo models. His landmark studies on the interplay of bcl-2, bcl-xl, p53, bad and bax during acetaminophen induced cell death and its prevention by grape seed proanthocyanidin extract has earned worldwide citations. His peer recognition and acknowledged service contributions are reflected by his election into multiple international professional organizations, such as the Society of Toxicology (SOT), Society of Free Radical Biology & Medicine (SFRBM), American Society of Pharmacology & Experimental Therapeutics (ASPET), American Association of Colleges of Pharmacy (AACP) and American College of Nutrition (ACN). Dr. Ray is an Associate Editor of Encyclopedia of Toxicology (3rd Ed, Elsevier, 2014), and serves on the editorial boards of multiple prestigious international journals, including ‘Archives of Toxicology’, ‘Oxidative Medicine & Cellular Longevity’, ‘Journal of Pharmaceutical Sciences and Pharmacology’, ‘Journal of Toxicological Education’ and ‘Experimental & Clinical Sciences’.

Based on his contributions to teaching, service and scholarship to health sciences in general, Dr. Ray received multiple prestigious awards, inc. the American Academy of Clinical Toxicology’s national research award (1996), ‘Fellow of the American College of Nutrition’ honor in 1999, David Newton Award for Excellence in Teaching Pharmacy (2005), the Biennial Abraham Krasnoff Memorial Award for Lifetime Scholarly Achievement (2008), Arnold & Marie Schwartz College of Pharmacy & Health Science’s ‘Wall-of-Fame’ honor (2011), the Society of Toxicology’s ‘Undergraduate Educator of the Year’ national award (2013), and the Manchester University’s ‘Outstanding Scholar of the Year’ award (2014). He currently serves on the SOT-NIH–NLM’s joint Toxlearn Project, SOT Undergraduate Task Force (2007 – present), and has previously served on the SOT’s Education Committee (2007 – 2010). In his lifetime, Dr. Ray has mentored research to numerous PharmD, MS, MD and PhD students in a number of areas of toxicology and biomedical sciences, made seminal contributions to the fields of pharmacology, toxicology, free radical biology, anticancer mechanism, phytochemicals, nutraceuticals & dietary supplements, and molecular safety sciences. Dr. Ray loves to promote ‘Lifelong Learning’ strategies to his students and clearly models his beliefs day in and day out. Visit URL: www.sidhartharay.com/ for more details.

Affiliations and Expertise

Department of Pharmaceutical Sciences, College of Pharmacy, Manchester University, Fort Wayne, IN, USA